NCT07605429 Rugonersen Angelman Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07605429—BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why NCT07605429 is a hot trial to watch
Angelman Syndrome is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. NCT07605429 is notable because it tests Rugonersen in a Phase 3 design with Change from baseline in the Bayley-4 cognition and/or expressive communication raw scores without caregiver input at Week 56. as a primary decision variable. The wider PatSnap topic query returned 23 trial records and 16 result records, so differentiation depends on evidence quality rather than activity alone.
PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07605429 |
| Official title | BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome. |
| Phase / status | Phase 3 / Not yet recruiting |
| Intervention | Rugonersen |
| Sponsor | Oak Hill Bio Corp. |
| Geography | Not reported |
| Enrollment | 165 |
| Primary endpoint | Change from baseline in the Bayley-4 cognition and/or expressive communication raw scores without caregiver input at Week 56. |
| Endpoint time frame | Baseline to week 56 |
| Primary completion | 2029-03-01 |
| Study completion | 2031-03-01 |
Design and endpoint interpretation
The design should be read as an evidence architecture, not just a phase label. The primary endpoint—Change from baseline in the Bayley-4 cognition and/or expressive communication raw scores without caregiver input at Week 56.—determines what uncertainty this study can resolve. The reported time frame is Baseline to week 56. Enrollment of 165 participants and geography in Not reported shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.
Benchmark readouts in the same clinical field
- Responder Analysis: Continued Benefit in Multiple Domains Assessed in the HALOS Study (Phase 1): -; Responders on Bayley-4 Expressive Communication(6-month, vs. Natural History) = 61 % .
- An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome (Phase 3): Incidence of Participants Experiencing Adverse Events in Active Treatment Group = 1 participants ; -; -.
- The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial (Phase 1): Safety = rugonersen had an acceptable safety and tolerability profile Met.
These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.
Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: Rugonersen (Phase 3; UBE3A).
Company & Deal Intelligence context: Oak Hill Bio Corp. — https://www.oakhillbio.com.
The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: randomized data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.
What to monitor next
Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.
Bottom line
NCT07605429 is a focused lens on Angelman Syndrome development. Its value will be determined by whether Rugonersen can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
